Vectura Group PLC (VEC)

153.76
+0.76(+0.50%)
  • Volume:
    911,379
  • Bid/Ask:
    1.78/1.85
  • Day's Range:
    153.23 - 154.15

VEC Overview

Prev. Close
153
Day's Range
153.23-154.15
Revenue
190.6M
Open
153.6
52 wk Range
97.57-163.8
EPS
0.2
Volume
911,379
Market Cap
910.33M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,790,724
P/E Ratio
7.59
Beta
0.46
1-Year Change
44.89%
Shares Outstanding
594,985,724
Next Earnings Date
13 Sept 2021
What is your sentiment on Vectura Group PLC?
or
Vote to see community's results!

Vectura Group PLC News

Vectura Group PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsBuyNeutralStrong BuyStrong BuyStrong Buy
SummaryBuyBuyStrong BuyStrong BuyStrong Buy

Vectura Group PLC Company Profile

Vectura Group PLC Company Profile

Employees
0

Vectura Group plc engages in the design, development, and supply of pharmaceutical products related to inhalation. Its products include flutiform, flutiform K-haler, Ultibro Breezhaler, Seebri Breezhaler, Enerzair Breezhaler, AirFluSal Forspiro, Airbufo Forspiro, Fluticasone Propionate and Salmeterol, Incruse Ellipta, Anoro Ellipta, Trelegy Ellipta, Relvar/Breo Ellipta, and Breelib. The company also provides formulation, process development and tech transfer, pharmaceutical analysis, product manufacturing, and device platforms services, as well as regulatory affairs, device vigilance, and pharmacovigilance services. In addition, it is developing VR315 (US), a generic Advair. Further, the company offers dry powder and pressurized metered dose inhalers, as well as vibrating mesh and jet nebulizers. Vectura Group plc was incorporated in 1997 and is based in Chippenham, the United Kingdom.

Read More
  • £958 million takeover yesterday by Carlyle Group.
    0
    • Anyone know why the share popped 13% today?
      1
      • Glaxo denied appeal.
        1
      • Glaxo denied appeal.
        1
    • https://www.gov.uk/government/news/government-invests-in-uk-developed-antibody-tests-from-uk-rapid-test-consortium
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.